Novel neuronal and endocrine autoantibody targets in autoimmune polyendocrine syndrome type 1

References

• Finnish-German APECED Consortium. An autoimmune disease, APECED, caused by mutations in a novel gene featuring two PHD-type zinc-finger domains. Nat Genet. 1997; 17 4: 399–403.
   PubMed Web of Science ®Google Scholar
• Nagamine K, Peterson P, Scott HS, . Positional cloning of the APECED gene. Nat Genet. 1997; 17 4: 393–398.
   PubMed Web of Science ®Google Scholar
• Anderson MS. Autoimmune endocrine disease. Curr Opin Immunol. 2002; 14 6: 760–764.
   PubMed Web of Science ®Google Scholar
• Mathis D, Benoist C. A decade of AIRE. Nat Rev Immunol. 2007; 7 8: 645–650.
   PubMed Web of Science ®Google Scholar
• Betterle C, Greggio NA, Volpato M. Clinical review: autoimmune polyglandular syndrome type 1. J Clin Endocrinol Metab. 1998; 83:1049–1055.
   PubMed Web of Science ®Google Scholar
• Clemente MG, Obermayer-Straub P, . Cytochrome P450 1A2 is a hepatic autoantigen in autoimmune polyglandular syndrome type 1. J Clin Endocrinol Metab. 1997; 82 5: 1353–1361.
   PubMed Web of Science ®Google Scholar
• Perheentupa J. APS-I/APECED: the clinical disease and therapy. Endocrinol Metab Clin North Am. 2002; 31 2: 295–320.
   PubMed Web of Science ®Google Scholar
• Alimohammadi M, Bjorklund P, Hallgren A, . Autoimmune polyendocrine syndrome type 1 and NALP5, a parathyroid autoantigen. New Engl J Med. 2008; 358:1018–1028.
   PubMed Web of Science ®Google Scholar
• Ekwall O, Hedstrand H, Grimelius L, . Identification of tryptophan hydroxylase as an intestinal autoantigen. Lancet. 1998; 352:279–283.
   PubMed Web of Science ®Google Scholar
• Ahonen P, Myllarniemi S, Sipila I, . Clinical variation of autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED) in a series of 68 patients. N Engl J Med. 1990; 322:1829–1836.
   PubMed Web of Science ®Google Scholar
• Perheentupa J. Autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy. J Clin Endocrinol Metab. 2006; 91 8: 2843–2850.
   PubMed Web of Science ®Google Scholar
• Ward L, Paquette J, Seidman E, Huot C, . Severe autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy in an adolescent girl with a novel AIRE mutation: response to immunosuppressive therapy. J Clin Endocrinol Metab. 1999; 84:844–852.
   PubMed Web of Science ®Google Scholar
• Cocco C, Meloni A, Boi F, Pinna G, . Median eminence dopaminergic nerve terminals: A novel target in autoimmune polyendocrine syndrome?. J Clin Endocrinol Metab. 2005; 90 7: 4108–4111.
   PubMed Web of Science ®Google Scholar
• Scherbaum WA, Bottazzo GF. Autoantibodies to vasopressin cells in idiopathic diabetes insipidus: evidence for an autoimmune variant. Lancet. 1983; 1:897–901.
   PubMed Web of Science ®Google Scholar
• Clifton-Bligh P, Lee C, Smith H, . The association of diabetes insipidus with hypoparathyroidism. Addison's disease and mucocutaneous candidiasis. Aust N Z J Med. 1980; 10 5: 548–551.
   PubMedGoogle Scholar
• Arvanitakis C, Knouss RF. Selective hypopituitarism. Impaired cell-mediated immunity and chronic mucocutaneous candidiasis. JAMA. 1973; 17:1492–1495.
   Google Scholar
• Bensing S, Fetissov SO, Mulder J, . Pituitary autoantibodies in autoimmune polyendocrine syndrome type 1. Proc Natl Acad Sci. 2007; 104 3: 949–954.
   PubMed Web of Science ®Google Scholar
• O'Dwyer DT, Smith AI, Matthew ML, . Identification of the 49-kDa autoantigen associated with lymphocytic hypophysitis as -enolase. J Clin Endocrinol Metab. 2002; 87:752–757.
   PubMed Web of Science ®Google Scholar
• Smith CJA, Oscarson M, Ronnblom L, . TSGA10 – A target for autoantibodies in Autoimmune Polyendocrine Syndrome Type 1 and Systemic Lupus Erythematosus. Scand J Immunol. 2011; 73 2: 147–153.
   PubMed Web of Science ®Google Scholar
• Perniola R, Falorni A, Clemente MG, . Organ-specific and non-organ-specific autoantibodies in children and young adults with autoimmune poly-endocrinopathy-candidiasis-ectodermal dystrophy (APECED). Eur J Endocrinol. 2000; 143:497–503.
   PubMed Web of Science ®Google Scholar
• Soderbergh A, Myhre AG, Ekwall O, . Prevalence and clinical associations of 10 defined autoantibodies in autoimmune polyendocrine syndrome type I. J Clin Endocrinol Metab. 2004; 89:557–562.
   PubMed Web of Science ®Google Scholar
• Husebye ES, Gebre-Medhin G, Tuomi T, . Autoantibodies against aromatic L-amino acid decarboxylase in autoimmune polyendocrine syndrome type I. J Clin Endocrinol Metab. 1997; 82 1: 147–150.
   PubMed Web of Science ®Google Scholar
• Husebye ES, Boe AS, Rorsman F, . Inhibition of aromatic L-amino acid decarboxylase activity by human autoantibodies. Clin Exp Immunol. 2000; 120 3: 420–423.
   PubMed Web of Science ®Google Scholar
• Fetissov SO, Bensing S, Mulder J, . Autoantibodies in autoimmune polyglandular syndrome type I patients react with major brain neurotransmitter systems. J Comp Neurol. 2009; 513 1: 1–20.
   PubMed Web of Science ®Google Scholar
• Scott HS, Heino M, Peterson P, . Common mutations in autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy patients of different origins. Mol Endocrinol. 1998; 12 8: 1112–1119.
   PubMedGoogle Scholar
• Rosatelli MC, Meloni A, Devoto M, . A common mutation in Sardinian autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy patients. Hum Genet. 1998; 103 4: 428–434.
   PubMed Web of Science ®Google Scholar
• Ewing DJ, Martyn CN, Young RJ, . The value of cardiovascular autonomic function tests: 10 years experience in diabetes. Diabetes Care. 1989; 8:491–498.
   Google Scholar
• Istenes I, Keresztes K, Hermanyi Z, . Relationship between autonomic neuropathy and hypertension–are we underestimating the problem?. Diabet Med. 2008; 25:863–866.
   PubMed Web of Science ®Google Scholar
• Boscolo S, Passoni M, Baldas V, . Detection of anti-brain serum antibodies using a semi-quantitative immunohistological method. J Immunol Meth. 2006; 20 309: 139–149.
   Google Scholar
• Yamamoto M, Iguchi G, Takeno R, . Adult combined GH, prolactin, and TSH deficiency associated with circulating PIT-1 antibody in humans. J Clin Invest. 2011; 121 1: 113–119.
   PubMed Web of Science ®Google Scholar
• Manto MU, Laute MA, Aguera M, . Effects of anti-glutamic acid decarboxylase antibodies associated with neurological diseases. Ann Neurol. 2007; 61 6: 544–551.
   PubMed Web of Science ®Google Scholar
• Valenzise M, Meloni A, Betterle C, . Chronic inflammatory demyelinating polyneuropathy as a possible novel component of autoimmune poly-endocrine-candidiasis-ectodermal dystrophy. Euro J Pediat. 2009; 168:237–240.
   PubMed Web of Science ®Google Scholar
• Björk E, Velloso LA, Kämpe O, Karlsson FA. GAD autoantibodies in IDDM, stiff-man syndrome, and autoimmune polyendocrine syndrome type I recognize different epitopes. Diabetes. 1994; 43 1: 161–165.
   PubMed Web of Science ®Google Scholar
• Tuomi T, Björses P, Falorni A, . Antibodies to glutamic acid decarboxylase and insulin-dependent diabetes in patients with autoimmune polyendocrine syndrome type I. J Clin Endocrinol Metab. 1996; 81 4: 1488–1494.
   PubMed Web of Science ®Google Scholar
• Brown FM, Kamalesh M, Adri MN, . Anti-adrenal medullary antibodies in IDDM subjects and subjects at high risk of developing IDDM. Diabetes Care. 1988; 11:30–33.
   PubMed Web of Science ®Google Scholar
• Zanone MM, Peakman M, Purewal T, . Autoantibodies to nervous tissue structures are associated with autonomic neuropathy in type 1 (insulin-dependent) diabetes mellitus. Diabetologia. 1993; 36:564–569.
   PubMed Web of Science ®Google Scholar
• Zanone MM, Favaro E, Catalfamo E, . Autonomic function and autoantibodies to autonomic nervous tissues at follow-up in a cohort of young patients with type 1 diabetes. Effects of serum from diabetic patients on human adrenergic cells. J Neuroimmunol. 2003; 139:66–75.
   PubMed Web of Science ®Google Scholar